Equity Profile

SMMT

Summit Therapeutics Inc.

Health CareBiotechnology$11.5B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:32 PM EDT

Summit Therapeutics Inc. Beats on EPS, Stock Up 3.02%

Metric	Actual	Expected	Surprise
EPS	$-0.15	$-0.21	+54.95%
Revenue	N/A	$0M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Summit Therapeutics Inc. Beats on EPS, Stock Up 3.02%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.15	$-0.21	+54.95%
Revenue	N/A	$0M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Summit Therapeutics reported a better-than-expected EPS for Q1-2026, which contributed to a 3.02% increase in stock price. The company did not provide revenue figures or any forward guidance, leaving investors with limited insights into future performance. The positive EPS surprise may indicate improved cost management or operational efficiencies.

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for any signs of improvement.

$-0.21

Revenue

Even though revenue expectations are low, any reported revenue could indicate progress in product development or market acceptance.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing innovative medicines for serious diseases. With a market cap of $16 billion, it operates in the health care sector, which is increasingly important as demand for new therapies continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In the last quarter (Q4-2025), Summit reported an EPS of $-0.14, which was better than the expected $-0.22, resulting in a positive stock reaction of 0.94%. However, revenue figures were not disclosed, leaving some uncertainty.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a loss of $-0.21 per share this quarter, with no revenue anticipated. The market is watching closely for any surprises in earnings or potential revenue.

Bull Case

If Summit can report a smaller loss than expected or even generate some revenue, it could signal positive momentum and boost investor confidence.

Bear Case

Conversely, if the company reports a larger loss or fails to provide any revenue, it may raise concerns about its financial health and future prospects.

Key Metrics to Watch

EPS

$-0.21

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for any signs of improvement.

Revenue

$0M

Even though revenue expectations are low, any reported revenue could indicate progress in product development or market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS be better than the consensus estimate of $-0.21?

A smaller loss could indicate improved operational efficiency and may positively influence investor sentiment.

Is there any revenue reported this quarter?

Any revenue, even if minimal, could signal progress in product development and market acceptance, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a smaller-than-expected loss this quarter, given the company's recent trend of beating EPS estimates.

Supporting Evidence

Summit has consistently surprised to the upside on EPS in recent quarters, with an 88% beat rate.

Options pricing suggests a larger move than historical averages, indicating that traders expect significant news.

The lack of revenue expectations may lead to lower thresholds for positive reactions.

Key Risk

If the EPS comes in better than $-0.21, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will help determine whether Summit is making progress in its product pipeline and financial health.

Bull Confirmed If

Reporting an EPS loss of less than $-0.21 and generating any revenue would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.21 without any revenue would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.24%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±10.2% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.7%

30d HV

84.0%

Calls (278K)P/C Ratio: 1.47Puts (169K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 9 of 23 (39%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 23 (61%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.3%, with a raw directional average of +2.4% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations and raises guidance, history suggests the stock could move up by an average of 2.37% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline of about 1.43% on the first day, as seen in past performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of drug development programs.
2Updates on any partnerships or collaborations that could impact revenue.
3Insights into cost management and operational efficiency improvements.
4Any guidance on future earnings or revenue expectations.
5Discussion on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Brown & Brown, Inc.

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for any signs of improvement.

$-0.21

Revenue

Even though revenue expectations are low, any reported revenue could indicate progress in product development or market acceptance.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a loss of $-0.21 per share this quarter, with no revenue anticipated. The market is watching closely for any surprises in earnings or potential revenue.

Bull Case

If Summit can report a smaller loss than expected or even generate some revenue, it could signal positive momentum and boost investor confidence.

Bear Case

Conversely, if the company reports a larger loss or fails to provide any revenue, it may raise concerns about its financial health and future prospects.

Key Metrics to Watch

EPS

$-0.21

Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for any signs of improvement.

Revenue

$0M

Even though revenue expectations are low, any reported revenue could indicate progress in product development or market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS be better than the consensus estimate of $-0.21?

A smaller loss could indicate improved operational efficiency and may positively influence investor sentiment.

Is there any revenue reported this quarter?

Any revenue, even if minimal, could signal progress in product development and market acceptance, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a smaller-than-expected loss this quarter, given the company's recent trend of beating EPS estimates.

Supporting Evidence

Summit has consistently surprised to the upside on EPS in recent quarters, with an 88% beat rate.

Options pricing suggests a larger move than historical averages, indicating that traders expect significant news.

The lack of revenue expectations may lead to lower thresholds for positive reactions.

Key Risk

If the EPS comes in better than $-0.21, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will help determine whether Summit is making progress in its product pipeline and financial health.

Bull Confirmed If

Reporting an EPS loss of less than $-0.21 and generating any revenue would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.21 without any revenue would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.24%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±10.2% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.7%

30d HV

84.0%

Calls (278K)P/C Ratio: 1.47Puts (169K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 9 of 23 (39%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations and raises guidance, history suggests the stock could move up by an average of 2.37% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline of about 1.43% on the first day, as seen in past performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of drug development programs.
2Updates on any partnerships or collaborations that could impact revenue.
3Insights into cost management and operational efficiency improvements.
4Any guidance on future earnings or revenue expectations.
5Discussion on market conditions and competitive landscape.